NovAccess Global Inc. (XSNX)
Chart Events
Performance Outlook
| Previous Close | 0.1750 |
| Open | 0.1750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1750 - 0.1750 |
| 52 Week Range | 0.1030 - 0.6000 |
| Volume | |
| Avg. Volume | 6,449 |
| Market Cap | 3.424M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.2220 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, announced that Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, received the prestigious Golden Axon Award at the World Brain Mapping Foundation (WBMF) Annual Congress, held on February 17, 2023, in Los Angeles, CA.
- ACCESSWIRE
NovAccess Global to Present at World Orphan Drug Congress
NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-25, 2023, near Washington, DC.
- ACCESSWIRE
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dwain Irvin and Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, will be presenting at the World Brain Mapping Foundation Annual Congress, scheduled to be held on Friday, February 17, 2023, in Los Angeles, CA.
